Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence

References

• Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008;48(Suppl 1):S93–S103.
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397–417.
   PubMed Web of Science ®Google Scholar
• Durand F, Graupera I, Gines P, et al. Pathogenesis of hepatorenal syndrome: implications for therapy. Am J Kidney Dis. 2016;67(2):318–328.
   PubMed Web of Science ®Google Scholar
• Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003;362(9398):1819–1827.
   PubMed Web of Science ®Google Scholar
• Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531–537.
   PubMed Web of Science ®Google Scholar
• Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–974.
   PubMed Web of Science ®Google Scholar
• Trawale JM, Paradis V, Rautou PE, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30(5):725–732.
   PubMed Web of Science ®Google Scholar
• Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (Baltimore, Md). 1996;23(1):164–176.
   PubMed Web of Science ®Google Scholar
• Arroyo V, Fernandez J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol. 2011;7(9):517–526.
   PubMed Web of Science ®Google Scholar
• KASL clinical practice guidelines for liver cirrhosis: ascites and related complications. Clin Mol Hepatol. 2018;24(3):230–277.
   PubMed Web of Science ®Google Scholar
• Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology (Baltimore, Md). 2004;39(3):841–856.
   PubMed Web of Science ®Google Scholar
• Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology (Baltimore, Md). 2009;49(6):2087–2107.
   PubMed Web of Science ®Google Scholar
• Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology (Baltimore, Md). 2013;57(4):1651–1653.
   PubMed Web of Science ®Google Scholar
• Wong F, Leung W, Al Beshir M, et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transplant. 2015;21(3):300–307.
   PubMed Web of Science ®Google Scholar
• Song T, Rossle M, He F, et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: a systematic review and meta-analysis. DigLiver Dis. 2018;50(4):323–330.
   Google Scholar
• Colle I, Laterre PF. Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Rev Gastroenterol Hepatol. 2018;12(2):173–188.
   PubMed Web of Science ®Google Scholar
• Papaluca T, Gow P. Terlipressin: current and emerging indications in chronic liver disease. J Gastroenterol Hepatol. 2018;33(3):591–598.
   PubMed Web of Science ®Google Scholar
• Freeman JG, Cobden I, Lishman AH, et al. Controlled trial of terlipressin (‘Glypressin’) versus vasopressin in the early treatment of oesophageal varices. Lancet. 1982;2(8289):66–68.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tristani FE, Khatri IM. Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man. Circulation. 1968;38(1):151–157.
   PubMed Web of Science ®Google Scholar
• Kew MC, Varma RR, Sampson DJ, et al. The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut. 1972;13(4):293–296.
   PubMed Web of Science ®Google Scholar
• Lenz K, Hortnagl H, Druml W, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology. 1991;101(4):1060–1067.
   PubMed Web of Science ®Google Scholar
• Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology (Baltimore, Md). 1999;30(4):870–875.
   PubMed Web of Science ®Google Scholar
• Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406.
   PubMed Web of Science ®Google Scholar
• Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (Baltimore, Md). 2002;36(4 Pt 1):941–948.
   Web of Science ®Google Scholar
• Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53(3):830–835.
   PubMed Web of Science ®Google Scholar
• Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352–1359.
   PubMed Web of Science ®Google Scholar
• Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology (Baltimore, Md). 2015;62(2):567–574.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360–1368.
   PubMed Web of Science ®Google Scholar
• Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18(2):152–156.
   PubMed Web of Science ®Google Scholar
• Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579–1589.e2.
   PubMed Web of Science ®Google Scholar
• Sharma P, Kumar A, Shrama BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689–1697.
   PubMed Web of Science ®Google Scholar
• Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–1298.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Choudhary NS, Sharma AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33(8):1187–1193.
   PubMed Web of Science ®Google Scholar
• Goyal O, Sidhu SS, Sehgal N, et al. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial. J Assoc Physicians India. 2016;64(9):30–35.
   PubMedGoogle Scholar
• Srivastava S, Shalimar, Vishnubhatla S, et al. Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome. J Clin Exp Hepatol. 2015;5(4):276–285.
   PubMed Web of Science ®Google Scholar
• Arora V, Maiwall R, Vijayaraghavan R, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology (Baltimore, Md). 2018.
   PubMed Web of Science ®Google Scholar
• Saif RU, Dar HA, Sofi SM, et al. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study. Indian J Gastroenterol. 2018;37(5):424–429.
   PubMed Web of Science ®Google Scholar
• Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499–505.
   PubMed Web of Science ®Google Scholar
• Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology (Baltimore, Md). 2016;63(3):983–992.
   PubMed Web of Science ®Google Scholar
• Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315–321.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45(11):1390–1402.
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Elia C, Sola E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955–961.
   PubMed Web of Science ®Google Scholar
• Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology (Baltimore, Md). 2010;51(1):219–226.
   PubMed Web of Science ®Google Scholar
• Piano S, Schmidt HH, Ariza X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018;16(11):1792–1800.e3.
   PubMed Web of Science ®Google Scholar
• Zheng JN, Han YJ, Zou TT, et al. Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. Expert Rev Gastroenterol Hepatol. 2017;11(11):1009–1018.
   Google Scholar
• Nanda A, Reddy R, Safraz H, et al. Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2018;52(4):360–367.
   PubMed Web of Science ®Google Scholar
• Sridharan K, Sivaramakrishnan G. Vasoactive agents for hepatorenal syndrome: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. J Gen Intern Med. 2018;33(1):97–102.
   PubMed Web of Science ®Google Scholar
• Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:Cd011532.
   PubMed Web of Science ®Google Scholar
• Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017;45(5):593–603.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(2):94–102.
   PubMed Web of Science ®Google Scholar
• Mattos AZ, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28(3):345–351.
   PubMed Web of Science ®Google Scholar
• Nassar AP Junior, Farias AQ, D’Albuquerque LAC, et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466.
   Web of Science ®Google Scholar
• Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol. 2011;43(1):175–184.
   PubMed Web of Science ®Google Scholar
• Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology (Baltimore, Md). 2010;51(2):576–584.
   PubMed Web of Science ®Google Scholar
• Sagi SV, Mittal S, Kasturi KS, et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010;25(5):880–885.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24(6):935–944.
   PubMed Web of Science ®Google Scholar
• Piano S, Morando F, Fasolato S, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol. 2011;55(2):491–496.
   PubMed Web of Science ®Google Scholar
• Caraceni P, Santi L, Mirici F, et al. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis. 2011;43(3):242–245.
   PubMedGoogle Scholar
• Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transplant. 2011;17(11):1328–1332.
   Google Scholar
• Fabrizi F, Aghemo A, Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res. 2013;37(6):588–601.
   PubMed Web of Science ®Google Scholar